Trigeminal Neuralgia (Tic Douloureux) – Pipeline Review, H1 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Trigeminal Neuralgia (Tic Douloureux) – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This latest Pharmaceutical and Healthcare disease pipeline guide Trigeminal Neuralgia – Pipeline Review, H1 2020, provides an overview of the Trigeminal Neuralgia (Central Nervous System) pipeline landscape.

Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. Symptoms include spontaneous attacks of pain or attacks triggered by things such as touching the face, chewing, speaking and brushing teeth, pain in areas supplied by the trigeminal nerve, including the cheek, jaw, teeth, gums, lips, or less often the eye and forehead.

The Pharmaceutical and Healthcare latest pipeline guide Trigeminal Neuralgia – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Trigeminal Neuralgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Trigeminal Neuralgia (Tic Douloureux) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0 and Preclinical stages are 4, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Trigeminal Neuralgia (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Trigeminal Neuralgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
  

Key Topics Covered:

• Introduction
• Report Coverage
• Trigeminal Neuralgia (Tic Douloureux) – Overview
• Trigeminal Neuralgia (Tic Douloureux) – Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Trigeminal Neuralgia (Tic Douloureux) – Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Trigeminal Neuralgia (Tic Douloureux) – Companies Involved in Therapeutics Development
• Amgen Inc
• Biogen Inc
• Biohaven Pharmaceutical Holding Company Ltd
• Grace Therapeutics LLC
• InMed Pharmaceuticals Inc
• Merz Pharma GmbH & Co KgaA
• Noveome Biotherapeutics Inc
• OliPass Corporation
• PixarBio Corp
• Trigeminal Neuralgia (Tic Douloureux) – Drug Profiles
• carbamazepine – Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• DKI-561 – Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• erenumab – Drug Profile
• GTX-201 – Drug Profile
• incobotulinumtoxin A – Drug Profile
• INM-405 – Drug Profile
• OLP-1002 – Drug Profile
• rimegepant – Drug Profile
• Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia – Drug Profile
• ST-266 – Drug Profile
• vixotrigine – Drug Profile
• Trigeminal Neuralgia (Tic Douloureux) – Dormant Projects
• Trigeminal Neuralgia (Tic Douloureux) – Product Development Milestones
• Featured News & Press Releases
• Jul 03, 2019: Biohaven starts enrolment in rimegepant’s trigeminal neuralgia trial
• Feb 27, 2018: PixarBio Corporation Clarifies Pathways to FDA Approval for NR14 to Treat Trigeminal Neuralgia and Post-Surgical Pain
• Sep 15, 2016: PixarBio CEO Frank Reynolds to Present NeuroRelease a Non-Addictive Morphine Replacement at the 2016 Aegis Capital Growth Conference in Las Vegas, NV on September 21, 2016
• Jun 27, 2016: PixarBio Promotes David Kaplan to Chief Commercial Officer, as NeuroRelease a Morphine Strength Non Addictive Pain Treatment Remains on Track for 2018 Launch
• Mar 30, 2016: PixarBio, the Developers of NeuroRelease A Revolutionary Morphine Strength, Non-Addictive Pain Treatment Appoints Glenn Reiser Vice President of External Affairs
• Mar 03, 2016: PixarBio’s Dr. Taunia Markvicka and Glenn Reiser to Discuss Breakthrough Data on Morphine Strength Non-Addictive Pain Treatment NeuroRelease at the 2016 Congress of Neurological Surgeons Spine Summit held in Orlando, FL March 17-18, 2016
• Nov 30, 2015: PixarBio’s Glenn Reiser to Present Data on NeuroRelease, a Breakthrough Non-opiate and Non-addictive Pain Platform, at the 2015 Life Sciences Summit in New York, NY
• Oct 26, 2015: PixarBio Announces USFDA OPD Submission of NeuroRelease TN for Orphan Drug Designation for Trigeminal Neuralgia
• Sep 23, 2014: Convergence Pharmaceuticals’ Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy
• Jun 16, 2014: Convergence Pharmaceuticals’ Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study
• Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
• Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study
• Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802
• Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia

Companies Mentioned

• Amgen Inc
• Biogen Inc
• Biohaven Pharmaceutical Holding Company Ltd
• Grace Therapeutics LLC
• InMed Pharmaceuticals Inc
• Merz Pharma GmbH & Co KgaA
• Noveome Biotherapeutics Inc
• OliPass Corporation
• PixarBio Corp

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/kg96ur

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900